Correspondence 0001193125-23-160720 from Lite Strategy, Inc. (LITS)
Lite Strategy, Inc.
Date: June 5, 2023 · CIK: 0001262104 · Accession: 0001193125-23-160720
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271481
Letter
MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego, California 92130
June 5,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Re: MEI Pharma, Inc.
Registration Statement on Form S-4
File No. 333-271481
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 the Rules and Regulations promulgated under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-4 (as amended, the “Registration Statement”) be accelerated to Tuesday, June 6, 2023, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Bryan S. Keighery of Morgan, Lewis & Bockius LLP at (617) 341-7269.
Thank you very much.
Very truly yours,
MEI Pharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP MEI Pharma, Inc. 11455 El Camino Real, Suite 250 San Diego, California 92130 June 5, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Re: MEI Pharma, Inc. Registration Statement on Form S-4 File No. 333-271481 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 the Rules and Regulations promulgated under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-4 (as amended, the “Registration Statement”) be accelerated to Tuesday, June 6, 2023, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Bryan S. Keighery of Morgan, Lewis & Bockius LLP at (617) 341-7269. Thank you very much. Very truly yours, MEI Pharma, Inc. By: /s/ David M. Urso Name: David M. Urso Title: Chief Executive Officer